We are live on ! Find out more
MOLN

Molecular Partners
MOLN

8 hedge funds and large institutions have $5.93M invested in Molecular Partners in 2022 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 8 → 8 (0)

0% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 3

1.49% less ownership

Funds ownership: 4.19% → 2.7% (-1.5%)

78% less capital invested

Capital invested by funds: $27.6M → $5.93M (-$21.6M)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
8
Holders Change
–
Holders Change %
0%
% of All Funds
0.13%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
–
Reduced
1
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citigroup
Citigroup
New York
+$61.8K
2
HNWAG
High Net Worth Advisory Group
Florida
+$10.3K
3
CS
Credit Suisse
Switzerland
+$8.91K

Top Sellers

Rank Fund Capital Flow
1
Federated Hermes
Federated Hermes
Pennsylvania
-$9.26M
2
Millennium Management
Millennium Management
New York
-$485K
3
Jane Street
Jane Street
New York
-$21.8K
4
UBS Group
UBS Group
Switzerland
-$12K

MOLN Hedge Fund Activity: Q2 2022 in Review

8 of the 5,958 institutional investors tracked by Wall St. Rank reported a position in Molecular Partners (MOLN) for Q2 2022, worth a combined $5.93M — down 78% from $27.6M a quarter earlier.

Fund positioning in MOLN was balanced in Q2 2022: 3 funds opened new positions, 3 closed out, 0 added to existing stakes and 1 trimmed.

The largest buyer was Citigroup, opening a new position worth an estimated $61.8K. The largest seller was Federated Hermes, exiting entirely with an estimated $9.26M sold.

  • 8 institutional investors held Molecular Partners (MOLN) as of Q2 2022, unchanged from Q1 2022.
  • Funds reported $5.93M of Molecular Partners stock for Q2 2022, down 78% quarter-over-quarter.
  • 3 funds opened new Molecular Partners positions in Q2 2022 and 3 closed out, a net change of 0 holders.
  • The largest Molecular Partners buyer in Q2 2022 was Citigroup, an estimated $61.8K added.
  • The largest Molecular Partners seller in Q2 2022 was Federated Hermes, an estimated $9.26M sold.

Based on aggregated 13F filings for Q2 2022.